Insulet Valuation
Is PODD * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PODD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PODD * (MX$2815.58) is trading above our estimate of fair value (MX$2311.14)
Significantly Below Fair Value: PODD * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PODD *?
Other financial metrics that can be useful for relative valuation.
What is PODD *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$11.71b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 7.3x |
Enterprise Value/EBITDA | 40.4x |
PEG Ratio | 3.3x |
Price to Earnings Ratio vs Peers
How does PODD *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 44.9x | ||
688271 Shanghai United Imaging Healthcare | 52.5x | 19.6% | CN¥103.6b |
COH Cochlear | 59.8x | 12.2% | AU$21.0b |
6869 Sysmex | 35x | 13.3% | JP¥1.6t |
AFX Carl Zeiss Meditec | 32.4x | 11.9% | €9.0b |
PODD * Insulet | 56.8x | 17.4% | Mex$11.7b |
Price-To-Earnings vs Peers: PODD * is expensive based on its Price-To-Earnings Ratio (56.8x) compared to the peer average (44.9x).
Price to Earnings Ratio vs Industry
How does PODD *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: PODD * is expensive based on its Price-To-Earnings Ratio (56.8x) compared to the Global Medical Equipment industry average (27.6x).
Price to Earnings Ratio vs Fair Ratio
What is PODD *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 56.8x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PODD *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$2,815.58 | Mex$3,949.33 +40.3% | 7.0% | Mex$4,513.21 | Mex$3,476.84 | n/a | 20 |
Apr ’25 | n/a | Mex$3,925.49 0% | 7.0% | Mex$4,488.53 | Mex$3,457.83 | n/a | 20 |
Mar ’25 | Mex$2,907.38 | Mex$4,047.30 +39.2% | 7.6% | Mex$4,615.41 | Mex$3,555.57 | n/a | 20 |
Feb ’25 | n/a | Mex$3,989.56 0% | 11.5% | Mex$4,637.71 | Mex$2,799.80 | n/a | 20 |
Jan ’25 | n/a | Mex$3,861.49 0% | 13.5% | Mex$4,598.72 | Mex$2,776.26 | n/a | 20 |
Dec ’24 | Mex$3,243.00 | Mex$3,767.33 +16.2% | 16.1% | Mex$4,796.96 | Mex$2,792.52 | n/a | 20 |
Nov ’24 | n/a | Mex$4,570.09 0% | 21.1% | Mex$6,448.26 | Mex$2,942.58 | n/a | 20 |
Oct ’24 | n/a | Mex$4,794.52 0% | 17.5% | Mex$6,232.10 | Mex$3,247.71 | n/a | 18 |
Sep ’24 | n/a | Mex$4,838.62 0% | 15.0% | Mex$5,970.04 | Mex$3,497.94 | n/a | 18 |
Aug ’24 | n/a | Mex$5,891.39 0% | 8.7% | Mex$6,397.50 | Mex$3,992.04 | n/a | 18 |
Jul ’24 | n/a | Mex$6,158.75 0% | 8.6% | Mex$6,676.01 | Mex$4,165.83 | n/a | 18 |
Jun ’24 | Mex$4,808.00 | Mex$6,158.75 +28.1% | 8.6% | Mex$6,676.01 | Mex$4,165.83 | n/a | 18 |
May ’24 | n/a | Mex$6,082.80 0% | 8.7% | Mex$6,765.15 | Mex$4,221.45 | n/a | 17 |
Apr ’24 | n/a | Mex$5,965.41 0% | 9.3% | Mex$6,758.40 | Mex$4,217.24 | n/a | 16 |
Mar ’24 | n/a | Mex$5,951.33 0% | 9.8% | Mex$6,788.59 | Mex$4,236.08 | Mex$2,907.38 | 16 |
Feb ’24 | Mex$5,363.75 | Mex$5,963.66 +11.2% | 11.7% | Mex$6,698.06 | Mex$4,133.66 | n/a | 16 |
Jan ’24 | n/a | Mex$6,063.18 0% | 12.0% | Mex$6,846.91 | Mex$4,225.52 | n/a | 16 |
Dec ’23 | n/a | Mex$5,847.51 0% | 12.0% | Mex$6,774.11 | Mex$4,180.59 | Mex$3,243.00 | 16 |
Nov ’23 | n/a | Mex$5,476.18 0% | 12.5% | Mex$6,829.76 | Mex$3,761.32 | n/a | 16 |
Oct ’23 | n/a | Mex$5,552.71 0% | 12.4% | Mex$6,871.54 | Mex$3,784.33 | n/a | 14 |
Sep ’23 | n/a | Mex$5,639.78 0% | 12.5% | Mex$7,039.52 | Mex$3,876.84 | n/a | 15 |
Aug ’23 | n/a | Mex$5,426.04 0% | 13.5% | Mex$7,196.25 | Mex$3,963.15 | n/a | 15 |
Jul ’23 | n/a | Mex$5,243.23 0% | 14.1% | Mex$6,848.49 | Mex$3,771.63 | n/a | 15 |
Jun ’23 | Mex$4,497.82 | Mex$5,385.05 +19.7% | 13.3% | Mex$6,824.03 | Mex$3,758.16 | Mex$4,808.00 | 16 |
May ’23 | n/a | Mex$5,830.29 0% | 14.9% | Mex$7,283.66 | Mex$3,876.46 | n/a | 17 |
Apr ’23 | n/a | Mex$5,915.28 0% | 14.8% | Mex$7,369.44 | Mex$3,922.11 | n/a | 18 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.